STAAR SURGICAL CO 8K

STAAR Surgical reported record Q1 2026 results with a return to profitability, strong growth led by China and the U.S., improved margins, and operational progress in manufacturing and ERP systems, detailed in a shareholder letter and earnings call announcement.

On May 13, 2026, STAAR Surgical Company reported its financial and operational results for the first quarter ended April 3, 2026, highlighting record first‑quarter net sales of $93.5 million (up 119.6% year-over-year), a return to profitability with net income of $5.2 million and Adjusted EBITDA of $24.4 million, materially improved gross margins to 73.6%, normalization of distributor inventory and strong growth in China including the launch of the higher-margin EVO+ ICL, continued double‑digit sales growth in the U.S. supported by expanded FDA indications, progress scaling its Nidau, Switzerland manufacturing facility to supply China tariff‑free, and the ongoing rollout of a new Oracle ERP system, all framed within a strategy focused on revenue growth, profit expansion, and innovation acceleration, and accompanied by an earnings call scheduled the same day at 5:30 p.m. Eastern.

Filing Facts

CIK

718937

Ticker

-

Form

8K

Source Type

sec

Accession

0000718937-26-000022

Alert Tier

7